PM405. Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
نویسندگان
چکیده
s | 47 scores. A linear regression analysis revealed that being male and married had significant positive associations with sexual arousal, sexual satisfaction, and/or sexual desire, while the presence of TD and a longer duration of illness were associated with poor sexual arousal and/or sexual desire. Additionally, sexual function was significantly associated with SWN-K and DAI scores in multivariate analysis. Conclusions: The acknowledgement and management of sexual dysfunction in patients with schizophrenia by clinicians may be important for improvement of their quality of life and adherence to medication. PM403 Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia Jung Suk Lee1, Byung Ook Lee2, Hui Woo Yoon2 1Jesaeng Hospital, Republic of Korea, 2National Health Insurance Service Ilsan Hospital, Republic of Korea Abstract Objective: Hyperprolactinemia is an important but often overlookedObjective: Hyperprolactinemia is an important but often overlooked side effect of antipsychotics. Addition of and switching to aripiprazole normalized antipsychotics-induced hyperprolactinemia in several studies. However, there was no study that directly compared the effectiveness and safety of both strategies. Method: A total 52 patients with antipsychotics-induced hyperprolactinemia were recruited. Aripiprazole was added to patients with mild hyperprolactinemia (serum prolactin level lower than 50ng/ml). Patients with severe hyperprolactinemia (serum prolactin level higher than 50ng/ml) were randomized to aripiprazole addition group (adding aripiprazole to previous antipsychotics) or switching group (switching previous antipsychotics to aripiprazole). Serum prolactin levels, menstrual disturbances, sexual dysfunctions, psychopathologies, quality of life were measured at weeks 0, 1, 2, 4, 6 and 8. Results: Both addition and switching strategies significantly reduced serum prolactin levels (F(1, 199)=76.09, p<0.001) and menstrual disturbances (χ2=63.86, df=5, p<0.001) over time and they improved sexual dysfunctions (χ2=12.03, df=5, p=0.03) in all groups. In patients with severe hyperprolactinemia, number of patients with hyperprolactinemia (χ2=6.30, df=1, p=0.01) and menstrual disturbance (χ2=4.31, df=1, p=0.04) in switching group was significantly lower than that in addition group at week 8. Conclusion: Both addition and switching strategies were effective in resolving antipsychotics-induced hyperprolactinemia and hyperprolactinemia related adverse events including menstrual disturbances and sexual dysfunctions. These findings suggest that switching to aripiprazole may be more effective in normalizing hyperprolactinemia and improving hyperprolactinemia related adverse events in patients with schizophrenia. PM405 Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial Chieh-Hsin Lin, MD, PhD, Yue-Cune Chang, PhD, Hsien-Yuan Lane,
منابع مشابه
Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
BACKGROUND Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed...
متن کاملAdd-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
IMPORTANCE In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy for positive and negative sympt...
متن کاملEffect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial
Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...
متن کامل5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic...
متن کاملEvaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
متن کامل